JP2018507470A - 高悪性度膀胱癌の化学療法に対する奏効を予測するシステムおよび方法 - Google Patents
高悪性度膀胱癌の化学療法に対する奏効を予測するシステムおよび方法 Download PDFInfo
- Publication number
- JP2018507470A JP2018507470A JP2017537902A JP2017537902A JP2018507470A JP 2018507470 A JP2018507470 A JP 2018507470A JP 2017537902 A JP2017537902 A JP 2017537902A JP 2017537902 A JP2017537902 A JP 2017537902A JP 2018507470 A JP2018507470 A JP 2018507470A
- Authority
- JP
- Japan
- Prior art keywords
- weka
- linear
- tom1
- treatment
- svmlight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 77
- 206010005003 Bladder cancer Diseases 0.000 title claims abstract description 28
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims abstract description 28
- 201000005112 urinary bladder cancer Diseases 0.000 title claims abstract description 28
- 238000002512 chemotherapy Methods 0.000 title abstract description 11
- 230000004044 response Effects 0.000 title description 14
- 238000010801 machine learning Methods 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims description 84
- -1 LOC647121 Proteins 0.000 claims description 75
- 241000288113 Gallirallus australis Species 0.000 claims description 60
- 238000004422 calculation algorithm Methods 0.000 claims description 40
- 238000013518 transcription Methods 0.000 claims description 32
- 230000035897 transcription Effects 0.000 claims description 32
- 101000798942 Homo sapiens Target of Myb protein 1 Proteins 0.000 claims description 29
- 102100034024 Target of Myb protein 1 Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102100036783 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims description 20
- 101000928218 Homo sapiens Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1 Proteins 0.000 claims description 20
- 101000918642 Homo sapiens Protein DDI1 homolog 2 Proteins 0.000 claims description 20
- 101000988245 Homo sapiens Protocadherin gamma-A4 Proteins 0.000 claims description 20
- 102100029130 Protein DDI1 homolog 2 Human genes 0.000 claims description 20
- 102100029260 Protocadherin gamma-A4 Human genes 0.000 claims description 20
- 102100035988 60S ribosomal protein L39 Human genes 0.000 claims description 19
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 19
- 102100025905 C-Jun-amino-terminal kinase-interacting protein 4 Human genes 0.000 claims description 19
- 102100037527 ER membrane protein complex subunit 2 Human genes 0.000 claims description 19
- 102100028823 Folliculin-interacting protein 2 Human genes 0.000 claims description 19
- 102100028953 Gelsolin Human genes 0.000 claims description 19
- 101000716179 Homo sapiens 60S ribosomal protein L39 Proteins 0.000 claims description 19
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 claims description 19
- 101001076862 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 4 Proteins 0.000 claims description 19
- 101000880998 Homo sapiens ER membrane protein complex subunit 2 Proteins 0.000 claims description 19
- 101001059639 Homo sapiens Folliculin-interacting protein 2 Proteins 0.000 claims description 19
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 claims description 19
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 claims description 19
- 101000630284 Homo sapiens Proline-tRNA ligase Proteins 0.000 claims description 19
- 101000738546 Homo sapiens Protein PTHB1 Proteins 0.000 claims description 19
- 101000602014 Homo sapiens Protocadherin gamma-B1 Proteins 0.000 claims description 19
- 101000843134 Homo sapiens Putative heat shock protein HSP 90-beta 2 Proteins 0.000 claims description 19
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 claims description 19
- 102100026126 Proline-tRNA ligase Human genes 0.000 claims description 19
- 102100037873 Protein PTHB1 Human genes 0.000 claims description 19
- 102100037555 Protocadherin gamma-B1 Human genes 0.000 claims description 19
- 102100031039 Putative heat shock protein HSP 90-beta 2 Human genes 0.000 claims description 19
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 claims description 18
- 101000971703 Homo sapiens Kinesin-like protein KIF1C Proteins 0.000 claims description 18
- 101000650158 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP1 Proteins 0.000 claims description 18
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 claims description 18
- 101000906815 Homo sapiens Putative uncharacterized protein C9orf129 Proteins 0.000 claims description 18
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 claims description 18
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 claims description 18
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 claims description 18
- 102100021525 Kinesin-like protein KIF1C Human genes 0.000 claims description 18
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 18
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 18
- 102100027550 NEDD4-like E3 ubiquitin-protein ligase WWP1 Human genes 0.000 claims description 18
- 102100022033 Presenilin-1 Human genes 0.000 claims description 18
- 102100023765 Putative uncharacterized protein C9orf129 Human genes 0.000 claims description 18
- 102100040597 Serine-tRNA ligase, mitochondrial Human genes 0.000 claims description 18
- 102100034241 Elongator complex protein 2 Human genes 0.000 claims description 17
- 101710167764 Elongator complex protein 2 Proteins 0.000 claims description 17
- 101000609335 Homo sapiens Pyrroline-5-carboxylate reductase 1, mitochondrial Proteins 0.000 claims description 17
- 101001076724 Homo sapiens RNA-binding protein 28 Proteins 0.000 claims description 17
- 101000630717 Homo sapiens Surfeit locus protein 4 Proteins 0.000 claims description 17
- 102100039407 Pyrroline-5-carboxylate reductase 1, mitochondrial Human genes 0.000 claims description 17
- 102100025872 RNA-binding protein 28 Human genes 0.000 claims description 17
- 102100026355 Surfeit locus protein 4 Human genes 0.000 claims description 17
- 102000012698 DDB1 Human genes 0.000 claims description 16
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 claims description 16
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 claims description 16
- 102100037487 Histone H1.0 Human genes 0.000 claims description 16
- 101001026554 Homo sapiens Histone H1.0 Proteins 0.000 claims description 16
- 101000958669 Homo sapiens Nucleus accumbens-associated protein 2 Proteins 0.000 claims description 16
- 101000683584 Homo sapiens Ribosome-binding protein 1 Proteins 0.000 claims description 16
- 101000740417 Homo sapiens Secretory carrier-associated membrane protein 2 Proteins 0.000 claims description 16
- 102100038140 Nucleus accumbens-associated protein 2 Human genes 0.000 claims description 16
- 102100023542 Ribosome-binding protein 1 Human genes 0.000 claims description 16
- 102100037233 Secretory carrier-associated membrane protein 2 Human genes 0.000 claims description 16
- 101150077768 ddb1 gene Proteins 0.000 claims description 16
- 102100021325 Antizyme inhibitor 1 Human genes 0.000 claims description 15
- 101001132833 Homo sapiens Mitochondrial ribosome-associated GTPase 2 Proteins 0.000 claims description 15
- 101000822339 Homo sapiens Protein transport protein Sec24D Proteins 0.000 claims description 15
- 101000666873 Homo sapiens Protein virilizer homolog Proteins 0.000 claims description 15
- 101001132279 Homo sapiens Ras-related protein Rab-2A Proteins 0.000 claims description 15
- 101000805481 Homo sapiens Vigilin Proteins 0.000 claims description 15
- 102100033820 Mitochondrial ribosome-associated GTPase 2 Human genes 0.000 claims description 15
- 102100022542 Protein transport protein Sec24D Human genes 0.000 claims description 15
- 102100038288 Protein virilizer homolog Human genes 0.000 claims description 15
- 102100034485 Ras-related protein Rab-2A Human genes 0.000 claims description 15
- 102100037814 Vigilin Human genes 0.000 claims description 15
- 108010035632 ornithine decarboxylase antizyme inhibitor Proteins 0.000 claims description 15
- 102100029374 Adapter molecule crk Human genes 0.000 claims description 14
- 101000919320 Homo sapiens Adapter molecule crk Proteins 0.000 claims description 14
- 101000986786 Homo sapiens Orexin/Hypocretin receptor type 1 Proteins 0.000 claims description 14
- 101001134134 Homo sapiens Oxidation resistance protein 1 Proteins 0.000 claims description 14
- 102100028141 Orexin/Hypocretin receptor type 1 Human genes 0.000 claims description 14
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims description 13
- 102100026559 Filamin-B Human genes 0.000 claims description 13
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims description 13
- 101000913551 Homo sapiens Filamin-B Proteins 0.000 claims description 13
- 101000937691 Homo sapiens Protein FAM24B Proteins 0.000 claims description 13
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 claims description 13
- 101000614798 Homo sapiens cAMP-dependent protein kinase type II-alpha regulatory subunit Proteins 0.000 claims description 13
- 102100027326 Protein FAM24B Human genes 0.000 claims description 13
- 102100033192 Puromycin-sensitive aminopeptidase Human genes 0.000 claims description 13
- 102100021204 cAMP-dependent protein kinase type II-alpha regulatory subunit Human genes 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 12
- 101000655536 Homo sapiens Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 claims description 11
- 102100035115 Testin Human genes 0.000 claims description 11
- 102100032349 Transforming growth factor-beta receptor-associated protein 1 Human genes 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 11
- 238000007637 random forest analysis Methods 0.000 claims description 11
- 102100032564 Golgin subfamily A member 2 Human genes 0.000 claims description 10
- 101001014629 Homo sapiens Golgin subfamily A member 2 Proteins 0.000 claims description 10
- 101000667353 Homo sapiens von Willebrand factor A domain-containing protein 1 Proteins 0.000 claims description 10
- 102100039759 von Willebrand factor A domain-containing protein 1 Human genes 0.000 claims description 10
- 101001098498 Homo sapiens Protein PAT1 homolog 1 Proteins 0.000 claims description 9
- 102100037041 Protein PAT1 homolog 1 Human genes 0.000 claims description 9
- 101001092004 Homo sapiens Rho GTPase-activating protein 21 Proteins 0.000 claims description 8
- 102100035753 Rho GTPase-activating protein 21 Human genes 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 230000004952 protein activity Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102100023466 GTP-binding protein 2 Human genes 0.000 claims 3
- 101000828869 Homo sapiens GTP-binding protein 2 Proteins 0.000 claims 3
- 101100502336 Komagataella pastoris FLD1 gene Proteins 0.000 claims 3
- 101100421128 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SEI1 gene Proteins 0.000 claims 3
- 101100510301 Arabidopsis thaliana KIN7B gene Proteins 0.000 claims 1
- 101100510303 Nicotiana tabacum NACK2 gene Proteins 0.000 claims 1
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 claims 1
- 108010080971 phosphoribulokinase Proteins 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000012549 training Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000013210 evaluation model Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- 102100026561 Filamin-A Human genes 0.000 description 2
- 101000913549 Homo sapiens Filamin-A Proteins 0.000 description 2
- 101150096429 PCDHGA4 gene Proteins 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 101100257994 Arabidopsis thaliana FAB2 gene Proteins 0.000 description 1
- 101710167754 Elongator complex protein 1 Proteins 0.000 description 1
- 102100039246 Elongator complex protein 1 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091006442 Mitochondrial phosphate transporters Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101000658425 Odontomachus monticola U-poneritoxin(01)-Om4a Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101710104373 SLIT-ROBO Rho GTPase-activating protein 3 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 238000013477 bayesian statistics method Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000013527 convolutional neural network Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
- G06N20/20—Ensemble learning
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Analytical Chemistry (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Primary Health Care (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本発明の主題は、特定の新生物疾患(例えば、膀胱癌)に罹患している患者の比較的大きいクラスに関するゲノム情報を比較的多数の機械学習アルゴリズムにかけて、対応する多数の予測モデルを特定する様々なコンピュータシステムおよび方法に関する。次いで予測モデルの精度上昇率を分析し、次いで精度上昇率が最も高いモデル(1つまたは複数)を用いて、予測に適したオミクス因子を特定する。
Claims (42)
- 高悪性度膀胱癌を有する患者の治療転帰を予測する方法であって、
前記患者から複数のオミクスデータを入手することと、
複数の機械学習アルゴリズムおよび事前に入手したオミクスデータを用いて複数のモデルを作製することと、
精度上昇率の測定基準を用いて、前記複数のモデルから高悪性度膀胱癌治療の治療転帰を予測する単一モデルを選択するか、予め決定した精度上昇率の測定基準に基づいて、高悪性度膀胱癌治療の治療転帰を予測する単一モデルを選択することと、
前記単一モデルおよび前記患者の複数のオミクスデータを用いて、分析エンジンにより予測転帰を計算することと
を含む、方法。 - 前記オミクスデータが、全ゲノムの示差的対象、エクソームの示差的対象、SNPデータ、コピー数データ、RNA転写データ、タンパク質発現データおよびタンパク質活性データからなる群より選択される、請求項1に記載の方法。
- 前記精度上昇率の測定基準が、精度上昇率、精度上昇率の分布、血中濃度曲線下面積の測定基準、R2、p値の測定基準、シルエット係数および混同行列からなる群より選択される、請求項1〜2のいずれか1項に記載の方法。
- 前記単一モデルを少なくとも100例のモデルのなかから選択する、請求項1〜3のいずれか1項に記載の方法。
- 前記単一モデルの精度上昇率の測定基準が、全モデルの上位四分位内にある、請求項1〜4のいずれか1項に記載の方法。
- 前記単一モデルの精度上昇率の測定基準が、全モデルの上位5%以内にある、請求項1〜5のいずれか1項に記載の方法。
- 前記単一モデルの精度上昇率の測定基準が、他のすべてのモデルを上回る、請求項1〜6のいずれか1項に記載の方法。
- 前記予測転帰が、治療が著効、治療が有効、治療が無効で安定および治療が無効で増悪からなる群より選択される、請求項1〜7のいずれか1項に記載の方法。
- 前記単一モデルが、NMFpredictor(線形)、SVMlight(線形)、SVMlight一次多項式カーネル(次数dの多項式)、SVMlight二次多項式カーネル(次数dの多項式)、WEKA SMO(線形)、WEKA j48樹木(樹木ベース)、WEKAハイパーパイプ(分布ベース)、WEKAランダムフォレスト(樹木ベース)、WEKAナイーブベイズ(確率論的/ベイズ)、WEKA JRip(ルールベース)、glmnet lasso(スパース線形)、glmnetリッジ回帰(スパース線形)およびglmnetエラスティックネット(スパース線形)からなる群より選択される分類器を用いる機械学習アルゴリズムを用いて作製されたものである、請求項1〜8のいずれか1項に記載の方法。
- 前記計算する段階が、絶対値が最小である所定の重みを有する前記単一モデルの特徴を選択する段階を含む、請求項1〜9のいずれか1項に記載の方法。
- 前記絶対値が最小である所定の重みが、前記単一モデルの全重みの上位4分の1以内にある、請求項10に記載の方法。
- 前記計算する段階に、前記単一モデルの少なくとも10個の異なる選択した特徴を用いる、請求項1〜11のいずれか1項に記載の方法。
- 前記特徴が、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1およびGSNからなる群より選択される遺伝子のRNA転写値である、請求項10に記載の方法。
- 前記遺伝子のRNA転写値をそれぞれの係数を用いて計算し、前記それぞれの係数に絶対値を用いて、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1、GSNの順序で重みを付ける、請求項13に記載の方法。
- 前記精度上昇率の測定基準が、精度上昇率、精度上昇率の分布、血中濃度曲線下面積の測定基準、R2、p値の測定基準、シルエット係数および混同行列からなる群より選択される、請求項1に記載の方法。
- 前記単一モデルを少なくとも100例のモデルのなかから選択する、請求項1に記載の方法。
- 前記単一モデルの精度上昇率の測定基準が、全モデルの上位四分位内にある、請求項1に記載の方法。
- 前記単一モデルの精度上昇率の測定基準が、全モデルの上位5%以内にある、請求項1に記載の方法。
- 前記単一モデルの精度上昇率の測定基準が、他のすべてのモデルを上回る、請求項1に記載の方法。
- 前記予測転帰が、治療が著効、治療が有効、治療が無効で安定および治療が無効で増悪からなる群より選択される、請求項1に記載の方法。
- 前記単一モデルが、NMFpredictor(線形)、SVMlight(線形)、SVMlight一次多項式カーネル(次数dの多項式)、SVMlight二次多項式カーネル(次数dの多項式)、WEKA SMO(線形)、WEKA j48樹木(樹木ベース)、WEKAハイパーパイプ(分布ベース)、WEKAランダムフォレスト(樹木ベース)、WEKAナイーブベイズ(確率論的/ベイズ)、WEKA JRip(ルールベース)、glmnet lasso(スパース線形)、glmnetリッジ回帰(スパース線形)およびglmnetエラスティックネット(スパース線形)からなる群より選択される分類器を用いる機械学習アルゴリズムを用いて作製されたものである、請求項1に記載の方法。
- 前記計算する段階が、絶対値が最小である所定の重みを有する前記単一モデルの特徴を選択する段階を含む、請求項1に記載の方法。
- 絶対値が最小である所定の重みが、前記単一モデルの全重みの上位4分の1以内にある、請求項22に記載の方法。
- 前記計算する段階に、前記単一モデルの少なくとも10個の異なる選択した特徴を用いる、請求項1に記載の方法。
- 前記特徴が、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1およびGSNからなる群より選択される遺伝子のRNA転写値である、請求項22に記載の方法。
- 前記遺伝子のRNA転写値をそれぞれの係数を用いて計算し、前記それぞれの係数に絶対値を用いて、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1、GSNの順序で重みを付ける、請求項25に記載の方法。
- 高悪性度膀胱癌を有する患者の治療転帰を予測する方法であって、
前記患者から複数のRNA転写データを入手することと、
モデルに前記患者の複数のRNA転写データを用いて、分析エンジンにより治療転帰スコアを計算することと
を含み、
前記モデルが、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1およびGSNからなる群より選択される遺伝子のRNA転写値を用いるものである、
方法。 - 前記複数のRNA転写データがポリA RNAから得られるものである、請求項27に記載の方法。
- 前記治療転帰スコアが、治療が著効、治療が有効、治療が無効で安定または治療が無効で増悪を示す、請求項27または28に記載の方法。
- 前記モデルが、NMFpredictor(線形)、SVMlight(線形)、SVMlight一次多項式カーネル(次数dの多項式)、SVMlight二次多項式カーネル(次数dの多項式)、WEKA SMO(線形)、WEKA j48樹木(樹木ベース)、WEKAハイパーパイプ(分布ベース)、WEKAランダムフォレスト(樹木ベース)、WEKAナイーブベイズ(確率論的/ベイズ)、WEKA JRip(ルールベース)、glmnet lasso(スパース線形)、glmnetリッジ回帰(スパース線形)およびglmnetエラスティックネット(スパース線形)からなる群より選択される分類器を用いる機械学習アルゴリズムを用いて作製されたものである、請求項27〜29のいずれか1項に記載の方法。
- 前記遺伝子のRNA転写値をそれぞれの係数を用いて計算し、前記それぞれの係数に絶対値を用いて、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1、GSNの順序で重みを付ける、請求項27〜30のいずれか1項に記載の方法。
- 前記治療転帰スコアが、治療が著効、治療が有効、治療が無効で安定または治療が無効で増悪を示す、請求項27に記載の方法。
- 前記モデルが、NMFpredictor(線形)、SVMlight(線形)、SVMlight一次多項式カーネル(次数dの多項式)、SVMlight二次多項式カーネル(次数dの多項式)、WEKA SMO(線形)、WEKA j48樹木(樹木ベース)、WEKAハイパーパイプ(分布ベース)、WEKAランダムフォレスト(樹木ベース)、WEKAナイーブベイズ(確率論的/ベイズ)、WEKA JRip(ルールベース)、glmnet lasso(スパース線形)、glmnetリッジ回帰(スパース線形)およびglmnetエラスティックネット(スパース線形)からなる群より選択される分類器を用いる機械学習アルゴリズムを用いて作製されたものである、請求項27に記載の方法。
- 前記遺伝子のRNA転写値をそれぞれの係数を用いて計算し、前記それぞれの係数に絶対値を用いて、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1、GSNの順序で重みを付ける、請求項27に記載の方法。
- 高悪性度膀胱癌を有する患者の治療転帰を予測する方法であって、
前記患者の複数のRNA転写値を入手し、前記RNA転写値が、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1およびGSNからなる群より選択される少なくとも2種類の遺伝子の値であることと、
機械学習アルゴリズムによって作製されたモデルに前記RNA転写値を用いて、前記患者の治療転帰を予測することと
を含む、方法。 - 前記機械学習アルゴリズムが、NMFpredictor(線形)、SVMlight(線形)、SVMlight一次多項式カーネル(次数dの多項式)、SVMlight二次多項式カーネル(次数dの多項式)、WEKA SMO(線形)、WEKA j48樹木(樹木ベース)、WEKAハイパーパイプ(分布ベース)、WEKAランダムフォレスト(樹木ベース)、WEKAナイーブベイズ(確率論的/ベイズ)、WEKA JRip(ルールベース)、glmnet lasso(スパース線形)、glmnetリッジ回帰(スパース線形)およびglmnetエラスティックネット(スパース線形)からなる群より選択される分類器を用いるものである、請求項35に記載の方法。
- 前記機械学習アルゴリズムが、glmnetエラスティックネット(スパース線形)分類器を用いるものである、請求項36に記載の方法。
- 前記遺伝子のRNA転写値をそれぞれの係数を用いて計算し、前記それぞれの係数に絶対値を用いて、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1、GSNの順序で重みを付ける、請求項35に記載の方法。
- 高悪性度膀胱癌治療の治療転帰の予測への複数のRNA転写値の使用であって、前記予測が、複数の機械学習アルゴリズムから得た単一モデルを用いるものであり、前記RNA転写値が、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1およびGSNからなる群より選択される遺伝子のものである、使用。
- 前記遺伝子のRNA転写値をそれぞれの係数を用いて計算し、前記それぞれの係数に絶対値を用いて、PCDHGA4、PCDHGB1、HSP90AB2P、SPAG9、DDI2、TOP1P2、AGAP1、BBS9、FNIP2、LOC647121、NFIC、TGFBRAP1、EPRS、C9orf129、SARS、RBM28、NACC2、GTPBP5、PRKAR2A、CDK8、FAM24B、CRK、RAB2A、SMAD2、ELP2、WWP1、KIF5B、RPL39、PSEN1、SURF4、TTC35、TOM1、TES、VWA1、GOLGA2、ARHGAP21、FLJ37201、KIAA1429、AZIN1、SCAMP2、H1F0、PYCR1、SEC24D、FLNB、PATL1、HDLBP、RRBP1、OXR1、GLB1、NPEPPS、KIF1C、DDB1、GSNの順序で重みを付ける、請求項39に記載の使用。
- 前記機械学習アルゴリズムが、NMFpredictor(線形)、SVMlight(線形)、SVMlight一次多項式カーネル(次数dの多項式)、SVMlight二次多項式カーネル(次数dの多項式)、WEKA SMO(線形)、WEKA j48樹木(樹木ベース)、WEKAハイパーパイプ(分布ベース)、WEKAランダムフォレスト(樹木ベース)、WEKAナイーブベイズ(確率論的/ベイズ)、WEKA JRip(ルールベース)、glmnet lasso(スパース線形)、glmnetリッジ回帰(スパース線形)およびglmnetエラスティックネット(スパース線形)からなる群より選択される分類器を用いるものである、請求項39に記載の使用。
- 前記機械学習アルゴリズムが、glmnetエラスティックネット(スパース線形)を用いるものである、請求項41に記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562105697P | 2015-01-20 | 2015-01-20 | |
US62/105,697 | 2015-01-20 | ||
US201562127546P | 2015-03-03 | 2015-03-03 | |
US62/127,546 | 2015-03-03 | ||
PCT/US2016/013959 WO2016118527A1 (en) | 2015-01-20 | 2016-01-19 | Systems and methods for response prediction to chemotherapy in high grade bladder cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018507470A true JP2018507470A (ja) | 2018-03-15 |
Family
ID=56417658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017537902A Ceased JP2018507470A (ja) | 2015-01-20 | 2016-01-19 | 高悪性度膀胱癌の化学療法に対する奏効を予測するシステムおよび方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11101038B2 (ja) |
EP (1) | EP3248127A4 (ja) |
JP (1) | JP2018507470A (ja) |
KR (1) | KR102116485B1 (ja) |
CN (1) | CN107548498A (ja) |
AU (2) | AU2016209478B2 (ja) |
CA (1) | CA2974199A1 (ja) |
IL (1) | IL253550B (ja) |
WO (1) | WO2016118527A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11101038B2 (en) | 2015-01-20 | 2021-08-24 | Nantomics, Llc | Systems and methods for response prediction to chemotherapy in high grade bladder cancer |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017290803A1 (en) | 2016-06-30 | 2019-01-24 | Nant Holdings Ip, Llc | Nant cancer vaccine |
CN109952611A (zh) * | 2016-08-03 | 2019-06-28 | 南托米克斯有限责任公司 | 达沙替尼响应预测模型及其方法 |
CN109543203B (zh) * | 2017-09-22 | 2023-04-18 | 山东建筑大学 | 一种基于随机森林的建筑冷热负荷预测方法 |
JP2021501422A (ja) * | 2017-10-30 | 2021-01-14 | ナントミクス,エルエルシー | テモゾロミド反応予測因子及び方法 |
US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
TWI787500B (zh) | 2018-04-23 | 2022-12-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
US20210228128A1 (en) * | 2018-05-08 | 2021-07-29 | Abbott Diabetes Care Inc. | Sensing systems and methods for identifying emotional stress events |
CN108611416B (zh) * | 2018-05-09 | 2020-12-29 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法 |
US20200118691A1 (en) * | 2018-10-10 | 2020-04-16 | Lukasz R. Kiljanek | Generation of Simulated Patient Data for Training Predicted Medical Outcome Analysis Engine |
JP2022504916A (ja) * | 2018-10-12 | 2022-01-13 | ヒューマン ロンジェヴィティ インコーポレイテッド | 癌の遺伝子および臨床データの統合分析のためのマルチオミクス検索エンジン |
CN109671499B (zh) * | 2018-10-22 | 2023-06-13 | 南方医科大学 | 一种直肠毒性预测系统构建方法 |
EP3912007A4 (en) * | 2019-01-10 | 2022-11-02 | Travera LLC | IDENTIFICATION OF CANCER THERAPIES |
US10515715B1 (en) | 2019-06-25 | 2019-12-24 | Colgate-Palmolive Company | Systems and methods for evaluating compositions |
US11368890B2 (en) * | 2020-06-30 | 2022-06-21 | At&T Intellectual Property I, L.P. | Predicting small cell capacity and coverage to facilitate offloading of macrocell capacity |
CN115565610B (zh) * | 2022-09-29 | 2024-06-11 | 四川大学 | 基于多组学数据的复发转移分析模型建立方法及系统 |
CN115631847B (zh) * | 2022-10-19 | 2023-07-14 | 哈尔滨工业大学 | 基于多组学特征的早期肺癌诊断系统、存储介质及设备 |
CN116013528B (zh) * | 2023-01-10 | 2023-11-24 | 中山大学孙逸仙纪念医院 | 结合fish检测的膀胱癌术后复发风险预测方法、装置及介质 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060195266A1 (en) * | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
WO2012009382A2 (en) * | 2010-07-12 | 2012-01-19 | The Regents Of The University Of Colorado | Molecular indicators of bladder cancer prognosis and prediction of treatment response |
JP2013000067A (ja) * | 2011-06-17 | 2013-01-07 | Toray Ind Inc | 膀胱ガン診断用組成物及び方法 |
WO2013090620A1 (en) * | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
WO2014043803A1 (en) * | 2012-09-20 | 2014-03-27 | Genomedx Biosciences, Inc. | Thyroid cancer diagnostics |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001035316A2 (en) | 1999-11-10 | 2001-05-17 | Structural Bioinformatics, Inc. | Computationally derived protein structures in pharmacogenomics |
WO2003079286A1 (en) | 2002-03-15 | 2003-09-25 | Pacific Edge Biotechnology Limited | Medical applications of adaptive learning systems using gene expression data |
EP1579383A4 (en) | 2002-10-24 | 2006-12-13 | Univ Duke | MODELING OF A BINARY PREVISIONAL TREE WITH SEVERAL PREDICTORS, AND ITS USE IN CLINICAL AND GENOMIC APPLICATIONS |
US9342657B2 (en) | 2003-03-24 | 2016-05-17 | Nien-Chih Wei | Methods for predicting an individual's clinical treatment outcome from sampling a group of patient's biological profiles |
CA2531967C (en) * | 2003-07-10 | 2013-07-16 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
US20050210015A1 (en) | 2004-03-19 | 2005-09-22 | Zhou Xiang S | System and method for patient identification for clinical trials using content-based retrieval and learning |
JP5813908B2 (ja) | 2004-04-09 | 2015-11-17 | ジェノミック ヘルス, インコーポレイテッド | 化学療法剤に対する応答を予測するための遺伝子発現マーカー |
RU2007124523A (ru) | 2004-12-30 | 2009-02-10 | ПРОВЕНТИС, Инк., (US) | Способы, системы и компьютерные программные продукты для разработки и использования прогнозных моделей для прогнозирования большинства медицинских случаев, оценки стратегий вмешательства и для одновременной оценки нерегулярности биологических маркеров |
WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
GB2444410B (en) | 2006-11-30 | 2011-08-24 | Navigenics Inc | Genetic analysis systems and methods |
US7899764B2 (en) | 2007-02-16 | 2011-03-01 | Siemens Aktiengesellschaft | Medical ontologies for machine learning and decision support |
US7844609B2 (en) | 2007-03-16 | 2010-11-30 | Expanse Networks, Inc. | Attribute combination discovery |
JP5745273B2 (ja) | 2007-11-30 | 2015-07-08 | クラリエント ダイアグノスティック サービシーズ, インコーポレイテッド | 化学療法のためのマーカーとしてのtle3 |
WO2010030794A1 (en) | 2008-09-10 | 2010-03-18 | Digital Infuzion, Inc. | Machine learning methods and systems for identifying patterns in data |
US8484225B1 (en) | 2009-07-22 | 2013-07-09 | Google Inc. | Predicting object identity using an ensemble of predictors |
US20110262921A1 (en) * | 2010-04-23 | 2011-10-27 | Sabichi Anita L | Test for the Detection of Bladder Cancer |
US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
CN110322924A (zh) | 2010-04-29 | 2019-10-11 | 加利福尼亚大学董事会 | 利用关于基因组模型的数据集成的途径识别方法(paradigm) |
KR102218512B1 (ko) | 2010-05-25 | 2021-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
WO2012030840A2 (en) * | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
EP2681709A4 (en) | 2011-03-04 | 2015-05-06 | Kew Group Llc | PERSONALIZED MEDICAL MANAGEMENT SYSTEM, NETWORKS AND ASSOCIATED METHODS |
AU2012267888A1 (en) | 2011-06-07 | 2014-01-30 | Caris Mpi, Inc. | Molecular profiling for cancer |
US9678075B2 (en) | 2011-06-10 | 2017-06-13 | Deutsches Krebsforschungszentrum | Prediction of recurrence for bladder cancer by a protein signature in tissue samples |
US20140199273A1 (en) | 2011-08-05 | 2014-07-17 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US9934361B2 (en) | 2011-09-30 | 2018-04-03 | Univfy Inc. | Method for generating healthcare-related validated prediction models from multiple sources |
EP2769321B1 (en) | 2011-10-21 | 2016-06-01 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
EP2644705A1 (en) | 2012-03-30 | 2013-10-02 | RWTH Aachen | Biomarker for bladder cancer |
US9767526B2 (en) | 2012-05-11 | 2017-09-19 | Health Meta Llc | Clinical trials subject identification system |
EP2669682B1 (en) | 2012-05-31 | 2017-04-19 | Heinrich-Heine-Universität Düsseldorf | Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer |
AU2013329319B2 (en) | 2012-10-09 | 2019-03-14 | Five3 Genomics, Llc | Systems and methods for learning and identification of regulatory interactions in biological pathways |
US20140143188A1 (en) | 2012-11-16 | 2014-05-22 | Genformatic, Llc | Method of machine learning, employing bayesian latent class inference: combining multiple genomic feature detection algorithms to produce an integrated genomic feature set with specificity, sensitivity and accuracy |
CA2905072A1 (en) | 2013-03-15 | 2014-09-25 | The Cleveland Clinic Foundation | Self-evolving predictive model |
CN105556523B (zh) | 2013-05-28 | 2017-07-11 | 凡弗3基因组有限公司 | Paradigm药物响应网络 |
CA2937051A1 (en) * | 2014-01-17 | 2015-07-23 | Ontario Institute For Cancer Research (Oicr) | Biopsy-driven genomic signature for prostate cancer prognosis |
WO2016118527A1 (en) | 2015-01-20 | 2016-07-28 | Nantomics, Llc | Systems and methods for response prediction to chemotherapy in high grade bladder cancer |
KR20190047108A (ko) | 2015-03-03 | 2019-05-07 | 난토믹스, 엘엘씨 | 앙상블-기반 연구 추천 시스템 및 방법 |
-
2016
- 2016-01-19 WO PCT/US2016/013959 patent/WO2016118527A1/en active Application Filing
- 2016-01-19 AU AU2016209478A patent/AU2016209478B2/en active Active
- 2016-01-19 US US15/543,418 patent/US11101038B2/en active Active
- 2016-01-19 CA CA2974199A patent/CA2974199A1/en not_active Withdrawn
- 2016-01-19 JP JP2017537902A patent/JP2018507470A/ja not_active Ceased
- 2016-01-19 CN CN201680008725.2A patent/CN107548498A/zh not_active Withdrawn
- 2016-01-19 KR KR1020177023267A patent/KR102116485B1/ko active IP Right Grant
- 2016-01-19 EP EP16740607.3A patent/EP3248127A4/en not_active Withdrawn
-
2017
- 2017-07-18 IL IL253550A patent/IL253550B/en not_active IP Right Cessation
-
2019
- 2019-05-10 AU AU2019203295A patent/AU2019203295A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060195266A1 (en) * | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
WO2012009382A2 (en) * | 2010-07-12 | 2012-01-19 | The Regents Of The University Of Colorado | Molecular indicators of bladder cancer prognosis and prediction of treatment response |
JP2013000067A (ja) * | 2011-06-17 | 2013-01-07 | Toray Ind Inc | 膀胱ガン診断用組成物及び方法 |
WO2013090620A1 (en) * | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
WO2014043803A1 (en) * | 2012-09-20 | 2014-03-27 | Genomedx Biosciences, Inc. | Thyroid cancer diagnostics |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11101038B2 (en) | 2015-01-20 | 2021-08-24 | Nantomics, Llc | Systems and methods for response prediction to chemotherapy in high grade bladder cancer |
Also Published As
Publication number | Publication date |
---|---|
WO2016118527A1 (en) | 2016-07-28 |
KR20180010176A (ko) | 2018-01-30 |
CN107548498A (zh) | 2018-01-05 |
US20180004905A1 (en) | 2018-01-04 |
AU2016209478B2 (en) | 2019-03-07 |
CA2974199A1 (en) | 2016-07-28 |
US11101038B2 (en) | 2021-08-24 |
KR102116485B1 (ko) | 2020-05-28 |
AU2016209478A1 (en) | 2017-08-10 |
IL253550A0 (en) | 2017-09-28 |
EP3248127A4 (en) | 2018-08-08 |
EP3248127A1 (en) | 2017-11-29 |
IL253550B (en) | 2020-05-31 |
AU2019203295A1 (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018507470A (ja) | 高悪性度膀胱癌の化学療法に対する奏効を予測するシステムおよび方法 | |
JP6609355B2 (ja) | 細胞系ゲノミクスからの薬物応答の患者特異的予測のためのシステムおよび方法 | |
KR102190299B1 (ko) | 인공신경망을 이용한 위암의 예후 예측 방법, 장치 및 프로그램 | |
Jakobsen et al. | Applying machine learning in motor activity time series of depressed bipolar and unipolar patients compared to healthy controls | |
Kurilov et al. | Assessment of modelling strategies for drug response prediction in cell lines and xenografts | |
JP2019527894A (ja) | ダサチニブ反応予測モデルおよびその方法 | |
He et al. | Identification of putative causal loci in whole-genome sequencing data via knockoff statistics | |
Zang et al. | Adaptive clinical trial designs in oncology | |
CA2877436C (en) | Systems and methods for generating biomarker signatures | |
Behrman et al. | Classification of patients with pain based on neuropathic pain symptoms: Comparison of an artificial neural network against an established scoring system | |
Zhang et al. | Trabeculae microstructure parameters serve as effective predictors for marginal bone loss of dental implant in the mandible | |
Hernández-Lorenzo et al. | On the limits of graph neural networks for the early diagnosis of Alzheimer’s disease | |
Hossain et al. | Application of skew-normal distribution for detecting differential expression to microRNA data | |
van Houwelingen | From model building to validation and back: a plea for robustness | |
Fisher et al. | Stochastic optimization of adaptive enrichment designs for two subpopulations | |
US10734095B2 (en) | Systems and methods for prioritizing variants of unknown significance | |
Li et al. | Robust nonparametric integrative analysis to decipher heterogeneity and commonality across subgroups using sparse boosting | |
Chen et al. | Artificial neural network prediction for cancer survival time by gene expression data | |
Bian et al. | Autoencoder-transformed transcriptome improves genotype-phenotype association studies | |
Farah et al. | DNA based disease prediction using pathway analysis | |
Jin | Biologically Interpretable Machine Learning Methods to Understand Gene Regulation for Disease Phenotypes | |
Yang | Applying machine learning to derive actionable insights in precision oncology | |
Chang et al. | High-dimensional causal mediation analysis by partial sum statistic and sample splitting strategy in imaging genetics application | |
Dadu | ML-assisted therapeutics for neurodegenerative disorders | |
Bao et al. | Explaining the genetic causality for complex diseases via deep association kernel learning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170815 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200130 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200609 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20201027 |